Sentences with phrase «lead a cancer model»

Not exact matches

In October 2016, writing in Mathematical Models and Methods in Applied Sciences, the team used a study of cancer in rats to test 13 leading tumor growth models to determine which could predict key quantities of interest relevant to survival, and the effects of various therModels and Methods in Applied Sciences, the team used a study of cancer in rats to test 13 leading tumor growth models to determine which could predict key quantities of interest relevant to survival, and the effects of various thermodels to determine which could predict key quantities of interest relevant to survival, and the effects of various therapies.

By studying human cancer cells and animal models of cancer in the lab, our researchers have shown that loss of PTEN leads to high levels of PI (3,4) P2, which could result in hyperactivation of AKT.

«Essentially, we are using the human placenta as a model to identify genes that play a key role in invasion in both the placenta and cancer,» wrote Chi Sutherland, a Ph.D. candidate leading the project, in an email.

«Complex models are needed to effectively evaluate PMed study designs, and this proof - of - concept trial validates the dog with cancer as a model for clinical evaluation of novel PMed approaches,» said Dr. Melissa Paoloni, the study's lead author and former director of the COTC.

Recently research published in Cancer Discovery showed that changing the schedules of drug administration can improve outcomes leading to more complete responses in mouse models of the disease.

Nevertheless, says lead study author Isabelle Deltour of the Institute of Cancer Epidemiology in Copenhagen, «The Nordic countries are a good model for studying the association» due to broad early adoption of the technology and thorough medical records.

A team of researchers, led by Ross Cagan, PhD, developed a multi-gene lung cancer model in the fruit fly Drosophila to better understand the mechanisms that promote tumors in NSCLC.

In summary, less Cdh1 prevents the normal function of APC / C, which eventually inhibits the degradation of PAX3, potentially leading to unregulated cell proliferation and cancer (melanoma in skin cell models).

«This model supported cancer development so strongly that some mice developed invasive squamous cell skin cancers similar to the patient's tumor,» said lead author Shadmehr Demehri, MD, PhD, a dermatologist and postdoctoral fellow.

Efforts aimed at finding better drug regimens would therefore greatly benefit from a mouse model with an intrinsic marker that can indicate different stages of pancreatic tumor formation leading to cancer and reflect the effects exerted by novel drug candidates.

In a new study published in Scientific Reports, Tokyo Medical and Dental University (TMDU)- led researchers investigated photodynamic detection of cancer stem cells in a glioma cell line, a model of a highly aggressive type of brain cancer.

«The result was an extensive inhibition of tumor growth and prevention of metastasis to the lung in HER2 - positive animal models of breast cancer,» notes Navasona Krishnan, Ph.D., a postdoctoral investigator in the Tonks lab who performed many of the experiments and is lead author on the paper reporting the results.

«Some unexpected phenotypes in animal models can actually lead to something very important in cancer biology that we didn't expect.

«We have provided a scalable and versatile 3D cancer model that shows a greater resemblance to natural cancer than 2D cultured cancer cells,» says the lead author, Professor Wei Sun of Tsinghua University in China and Drexel University in the United States.

«We demonstrated that the co-administration of the iRGD peptide with the particles can enhance the effectiveness of pancreatic cancer treatment in the tumor model, leading to increased tumor shrinkage, disappearance of metastases and enhanced animal survival» said Meng, an adjunct assistant professor of nanomedicine.

«The current model asserts CNAs are acquired gradually and sequentially over extended periods of time, leading to successively more malignant stages of cancer,» said Nicholas Navin, Ph.D., professor of Genetics at The University of Texas MD Anderson Cancer Center, and lead author of the cancer,» said Nicholas Navin, Ph.D., professor of Genetics at The University of Texas MD Anderson Cancer Center, and lead author of the Cancer Center, and lead author of the paper.

In a development that could lead to a new generation of drugs to precisely treat a range of diseases, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time designed a drug candidate that decreases the growth of tumor cells in animal models in one of the hardest to treat cancers — triple negative breast cancer.

Now, researchers from the Perelman School of Medicine, University of Pennsylvania have shown that when the enzyme key to cutting and pasting segments of DNA hits so - called «off - target» spots on a chromosome, the development of immune cells can lead to cancer in animal models.

In particular, more work is needed to determine the safety of this therapy in advanced mouse models that can more accurately predict safety in humans, and its efficacy specifically against metastatic cancer, which is the leading cause of cancer - related deaths.

Scientists, led by Ottar Rolfssonat the University of Iceland, have built a mathematical model to examine the metabolism of breast epithelium — as the majority of breast cancers originate from these cells.

Therefore, his team, led by postdoctoral fellow Gayatri Arun, set out to discover what would happen if mice that model human metastatic breast cancer were bred with the mice lacking Malat1.

He said experiments are under way to test the two - drug combination in laboratory models of metastasis - prone prostate cancer, leading eventually to tests in mouse models.

Additionally, the study showed that genetic knockdown of RASAL2 gene can lead to reduced metastasis in breast cancer mouse model.

«Our study is among the first to use induced pluripotent stem cells as the foundation of a model for cancer,» said lead author Dung - Fang Lee, PhD, a postdoctoral fellow in the Department of Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai.

In a study presented at the 2016 San Antonio Breast Cancer Symposium, UNC Lineberger researchers led by Katherine Hoadley, PhD, reported they developed a model that can predict which triple negative breast cancer patients will respond to chemothCancer Symposium, UNC Lineberger researchers led by Katherine Hoadley, PhD, reported they developed a model that can predict which triple negative breast cancer patients will respond to chemothcancer patients will respond to chemotherapy.

Furthermore, the same technologies used to create genetic models of cancer show promise as gene therapies capable of repairing mutations that lead to a range of diseases.

Franziska Michor (Dana - Farber Cancer Institute)-- Research done at the computational biology and bioinformatics laboratory of Dr. Michor has led to the first clinical trials based on the evolutionary mathematical modeling of cCancer Institute)-- Research done at the computational biology and bioinformatics laboratory of Dr. Michor has led to the first clinical trials based on the evolutionary mathematical modeling of cancercancer.

Under the new model — to which Stanford University, Memorial Sloan Kettering Cancer Center and other major institutions agreed — nearly 300 researchers specializing in the white - hot field of cancer immunology across the country will be following the lead of this central steering committee in determining the direction of their resCancer Center and other major institutions agreed — nearly 300 researchers specializing in the white - hot field of cancer immunology across the country will be following the lead of this central steering committee in determining the direction of their rescancer immunology across the country will be following the lead of this central steering committee in determining the direction of their research.

Other Institutions also belong to the Campus: the University of Milan; Cogentech, an IFOM - IEO consortium committed to developing leading genomic technologies (nanotechnologies, proteomics, bioinformatics, disease models), the European School of Molecular Medicine (SEMM), that organizes training in emerging sectors of Biomedicine, offering the first European PhDs in Molecular Medicine, Medical Nanotechnologies, Foundations of the Life Sciences and their Ethical Consequences; Genextra, a biotech company whose mission is to develop new therapies against cancer and aging - related disease; Biopolo, a not for profit company involved in the technological transfer of basic research to the productive system.

In the research published in the journal Scientific Reports, cancer risk climbs in cells close to heavily damaged cells, and it led to twice or higher increase in cancer incidence compared with conventional models for a Mars mission.

«Biologic models and early clinical evidence suggest that these fusions lead to oncogene addiction regardless of tissue of origin and, in aggregate, may be implicated in up to 1 % of all solid tumors,» wrote the study authors, led by Alexander Drilon, MD, of Memorial Sloan Kettering Cancer Center in New York.

Kessler is proud to be part of one only nine federally - designated Model Systems for the treatment and research of both spinal cord and brain injuries, a distinction shared with Kessler Foundation, and also leads the field in the care of individuals with stroke, neurologic diseases, amputation, orthopedic trauma, cancer and cardiac conditions.

Early observations suggesting that the virus might attack cancer in part by damaging blood vessels that feed tumor growth led the SillaJen team to strike up a collaboration with McDonald, an expert in tumor vasculature, to investigate the virus's mechanism of action in animal models.

This approach has led to the finding that activated fibroblasts in the tumor stroma mediate immune suppression in several mouse models of cancer, including the autochthonous model of pancreatic ductal adenocarcinoma of the Tuveson lab.

In addition to her expertise in tumor biology and a broad network of connections with leading scientists and clinicians in cancer research and clinical oncology, Dr. Almog has extensive hands - on experience with a variety of techniques ranging from the molecular level (DNA, RNA and proteins) to tissue, organ and mouse models in cancer biology, as well as extensive experience in project management and program coordination.

The scientists looked at this model and found it comes with a major caveat — instead of getting slower over time, some cells start growing at a faster rate as they age, which can result in mutations that lead to cancer cells.

New models championed by not - for - profits like the Cancer Research Institute can lead the way towards a systemic change in funding structures that more efficiently capitalize on the phenomenal discoveries taking place in both the lab and the clinic.

The model will describe cellular pathways that contribute to tumor formation and explain in detail how the genetic disposition of an individual can activate expression of genes that drive uncontrolled cell growth and lead to cancer.

Knocking out or blocking the activity of Nrp1 on regulatory T cells in mouse models of several human cancers, including the deadly skin cancer melanoma, led to reduced, delayed or complete elimination of the tumors.

Having discovered a genetic «key» (called P - TEFb) that is important in both cancer cell growth and immune cell differentiation, they tested the drugs on a mouse model for uveitis, an incurable eye condition in which the immune system mistakenly attacks healthy tissue leading to inflammation of the uvea (the middle layer of the eye).

In addition, we asked whether parity leads to persistent STAT5 activation in classical transgenic models of breast cancer.

Berman faculty have led or served on committees of the National Academy of medicine related to human and to animal research and led work for the National Cancer Institute creating model national guidance on informed consent; Berman faculty have served on multiple Data Safety and Monitoring Boards for federally and privately funded trials including the recent NIH sponsored ebola trials.

Other mouse models have shown that a hypochloric stomach environment leads to enteric bacterial overgrowth, which may play a role in gastric atrophy, metaplasia, and cancer.